Drug Trial Radar · NCT04005690
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 1, 2019
Primary completion
Jun 1, 2027
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- OHSU Knight Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Association for Cancer Research; Oregon Health and Science University; Genentech, Inc.; Cardiff Oncology
- First posted
- Jul 2, 2019
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, or AZD5305, or tremelimumab will work better than standard treatments in patients with pancreatic cancer.
Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma
Interventions
CobimetinibDrug
Given PO
OlaparibDrug
Given PO
OnvansertibDrug
Given PO
AzenosertibDrug
Given PO
SaruparibDrug
Given PO
TremelimumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baselineTime frame: Changes in tumor biology from baseline (i.e., Day 0) and on-treatment biopsy (i.e., 10 days from start of study intervention)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
OHSU Knight Cancer Institute
Portland, Oregon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.